Design, synthesis and biological evaluation of novel dithiocarbamate-substituted diphenylaminopyrimidine derivatives as BTK inhibitors

Bioorganic & Medicinal Chemistry
Zheng ZhaiYuxin Yin

Abstract

Bruton's tyrosine kinase (BTK) has emerged as an attractive target related to B-lymphocytes dysfunctions, especially hematologic malignancies and autoimmune diseases. In our study, a series of diphenylaminopyrimidine derivatives bearing dithiocarbamate moieties were designed and synthesized as novel BTK inhibitors for treatment of B-cell lymphoma. Among all these compounds, 30ab (IC50 = 1.15 ± 0.19 nM) displays similar or more potent inhibitory activity against BTK than spebrutinib (IC50 = 2.12 ± 0.32 nM) and FDA approved drug ibrutinib (IC50 = 3.89 ± 0.57 nM), which is attributed to close binding of 30ab with BTK predicted by molecular docking. In particular, 30ab exhibits enhanced anti-proliferative activity against B-lymphoma cell lines at the IC50 concentration of 0.357 ± 0.02 μM (Ramos) and 0.706 ± 0.05 μM (Raji), respectively, almost 10-fold better than ibrutinib and spebrutinib. In addition, 30ab displays stronger selectivity on B-cell lymphoma over other cancer cell lines than spebrutinib. Furthermore, 30ab efficiently blocks BTK downstream pathways and results in apoptosis of cancer cells. In vivo xenograft model evaluation demonstrates the significant efficacy and broad safety margin of 30ab in treatment of B-cell lym...Continue Reading

References

Mar 25, 2014·Nature Reviews. Cancer·Rudi W HendriksLaurens P Kil
Jul 18, 2014·Current Opinion in Oncology·Loic Ysebaert, Anne-Sophie Michallet
Feb 24, 2015·Bioorganic & Medicinal Chemistry Letters·Wendy B YoungKevin S Currie
Mar 1, 2015·European Journal of Medicinal Chemistry·Ri-Dong LiRun-Tao Li
Apr 14, 2015·Expert Review of Anticancer Therapy·Dai ChiharaChristopher R Flowers
Jul 15, 2015·Bioorganic & Medicinal Chemistry·Xinge ZhaoHua Xiang
Jul 19, 2015·Bioorganic & Medicinal Chemistry·Emmanuel S AkinboyeOladapo Bakare
Aug 19, 2015·Bioorganic & Medicinal Chemistry·Xinge ZhaoHua Xiang
Oct 22, 2016·ACS Chemical Biology·Adam R JohnsonWendy B Young
Dec 30, 2016·Nature Reviews. Clinical Oncology·Anas YounesJulie Vose
Mar 25, 2017·ACS Medicinal Chemistry Letters·Yanke LiangNathanael S Gray
Jul 1, 2017·Expert Opinion on Investigational Drugs·T Seiler, M Dreyling
Dec 5, 2017·Bioorganic & Medicinal Chemistry Letters·Wataru KawahataMasaaki Sawa
Nov 26, 2018·Bioorganic & Medicinal Chemistry·Lixue ChenYoujun Xu
Feb 2, 2019·Archives of Pharmacal Research·Hyung-Ook Kim
Jun 18, 2019·Bioorganic & Medicinal Chemistry·Keriann M BackusSean M Maddox

❮ Previous
Next ❯

Citations

Mar 20, 2021·European Journal of Medicinal Chemistry·Jiakuo LiuTiantai Zhang
Oct 20, 2020·Bioorganic Chemistry·Sangita Dattatray ShindeNagula Shankaraiah

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.

Autoimmune Diseases

Autoimmune diseases occur as a result of an attack by the immune system on the body’s own tissues resulting in damage and dysfunction. There are different types of autoimmune diseases, in which there is a complex and unknown interaction between genetics and the environment. Discover the latest research on autoimmune diseases here.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis